Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Trial ID or NCT#

NCT00352534

Status

not recruiting iconNOT RECRUITING

Purpose

This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.

Official Title

Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

Eligibility Criteria

Ages Eligible for Study: Younger than 29 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Neyssa Marina
Juan Carlos Fernandez-Miranda
Juan Carlos Fernandez-Miranda
Pituitary tumors neurosurgeon, Skull base neurosurgeon, Brain tumor surgeon, Neurosurgeon, Cerebrovascular neurosurgeon, Epilepsy neurosurgeon, Pain neurosurgeon, Pediatric neurosurgeon
Professor of Neurosurgery and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535

View on ClinicalTrials.gov